Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 participantsStarted Oct 2024

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +29 more locations

RECRUITINGPHASE1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Iambic Therapeutics, Inc243 participantsStarted Mar 2024

La Jolla, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +42 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Phase 1/1b Study of IAM1363 in HER2 Cancers